USA flag logo/image

An Official Website of the United States Government

Bioengineering of a New Decoy Receptor Drug Delivery Technology

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
94072
Program Year/Program:
2009 / SBIR
Agency Tracking Number:
NS066514
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
ARMAGEN TECHNOLOGIES, INC.
26679 Agoura Rd. #100 Calabasas, CA -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2009
Title: Bioengineering of a New Decoy Receptor Drug Delivery Technology
Agency: HHS
Contract: 1R43NS066514-01
Award Amount: $111,999.00
 

Abstract:

DESCRIPTION (provided by applicant): Decoy receptors are potential new pharmaceuticals to treat brain diseases, such as brain injury, spinal cord injury, stroke, or neurodegeneration. However, decoy receptor drugs are large molecule pharmaceuticals that do not cross the blood-brain barrier (BBB). The present work will produce a novel recombinant fusion protein that is able to both (a) bind a human BBB receptor to trigger transport into the brain, and (b) bind human tumor necrosis factor (TNF)-1, to block cy toxic effects of this inflammatory cytokine. A new approach to the BBB delivery of large molecules such decoy receptors is the molecular Trojan horse technology. A bi-functional fusion protein is produced with genetic engineering, wherein the decoy recepto r extracellular domain (ECD) is fused to a BBB molecular Trojan horse. The latter is a genetically engineered monoclonal antibody (MAb) that is able to cross the human BBB by receptor-mediated transcytosis on endogenous BBB peptide transport systems. The p resent work will produce a novel fusion gene encoding the ECD of the human TNF receptor type II and a genetically engineered MAB molecular Trojan horse, which will allow the production of the corresponding fusion protein, AGT-110. The fusion protein genes will be incorporated in a eukaryotic expression vector followed by permanent transfection of host cells. These phase I SBIR studies will enable production of a permanently transfected host cell line for future manufacturing of AGT-110. PUBLIC HEALTH RELEVANCE: Decoy receptors are potential new pharmaceuticals to treat brain diseases, such as brain injury, spinal cord injury, stroke, or neurodegeneration. However, decoy receptor drugs are large molecule pharmaceuticals that do not cross the blood-brai n barrier (BBB). The present work will produce a novel recombinant fusion protein that is able to both (a) bind a human BBB receptor to trigger transport into the brain, and (b) bind human tumor necrosis factor-alpha, to block cytoxic effects of this infla mmatory cytokine.

Principal Investigator:

Kawai Hui

Business Contact:

Paul Lee
rboado@armagen.com
Small Business Information at Submission:

ARMAGEN TECHNOLOGIES, INC.
ARMAGEN TECHNOLOGIES, INC. 914 COLORADO AVE SANTA MONICA, CA 90401

EIN/Tax ID: 770626715
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No